FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149130129> ?p ?o ?g. }

• W2149130129 endingPage "1670" @default.
• W2149130129 startingPage "1655" @default.
• W2149130129 abstract "Background: Both gabapentin and pregabalin are approved for the management of postherpetic neuralgia (PHN), although dosing and pharmacokinetic differences between these medications may affect their use in actual practice. Objectives: This study was conducted to characterize the use of gabapentin and pregabalin in the management of PHN in clinical practice, with a specific focus on the doses actually prescribed and changes in the use of other neuropathic pain-related medications after the initiation of gabapentin or pregabalin. Methods: The PharMetrics Patient-Centric Database was used to identify patients with PHN who were newly prescribed gabapentin or pregabalin between September 1, 2005, and March 31, 2006. The out-comes of interest were the prevalence of comorbidities, exposure to neuropathic pain-related medications (ie, the proportions of patients receiving ⩾1 prescription for these medications in the 6-month periods before and after the date of the first gabapentin or pregabalin prescription), and attainment of therapeutic dose levels (gabapentin, ⩾1800 rag/d; pregabalin, ⩾150 rag/d). Results: The database search identified 151 patients with PHN who were newly prescribed gabapentin (57.0% female; mean [SD] age, 55.8 [11.3] years) and 100 patients who were newly prescribed pregabalin (62.0% female; mean age, 52.8 [9.4] years). The prevalence of comorbidities did not differ significantly between recipients of prescriptions for gabapentin or pregabalin, with the exception of hyperlipidemia, which was more prevalent in those prescribed gabapentin (33.8% vs 22.0%, respectively; P = 0.044), and depression, which was more prevalent in those prescribed pregabalin (12.0% vs 4.6%, respectively; P = 0.031). In the pretreatment period, those who were prescribed pregabalin had significantly greater use of long-acting opioids (P = 0.005), anticonvulsants (P < 0.001), selective norepinephrine reuptake inhibitors (P < 0.001), and the lidocaine 5% patch (P = 0.005) compared with those prescribed gabapentin. Use of any opioid increased from pretreatment to follow-up in those prescribed gabapentin, significantly so in those who received ⩾2 opioid prescriptions (P = 0.016). Use of any opioid decreased significantly from pre-treatment to follow-up in those prescribed pregabalin (P = 0.005), particularly in those who received >2 opi-old prescriptions (P = 0.004). Tramadol use decreased significantly in those prescribed gabapentin (P = 0.045), and anticonvulsant use decreased significantly in those prescribed pregabalin (P = 0.004). Among patients prescribed gabapentin or pregabalin who received 1 prescription, 2 consecutive prescriptions, and ⩾3 consecutive prescriptions, a greater proportion of those prescribed pregabalin attained therapeutic dose levels by their first, second, and third consecutive prescriptions compared with those prescribed gabapentin (69.0% vs 3.5%, respectively [P < 0.001]; 71.4% vs 21.7% [P < 0.001]; and 89.3% vs 46.2% [P < 0.001], respectively). Conclusions: In these patients with PHN in the usual-care setting, opioid use increased after the initiation of gabapentin and decreased after the initiation of pregabalin. Few of those prescribed gabapentin received a prescription for a therapeutic dose, whereas a greater proportion of patients who were prescribed pregabalin received a prescription for a therapeutic dose." @default.
• W2149130129 created "2016-06-24" @default.
• W2149130129 creator A5030523303 @default.
• W2149130129 creator A5049491343 @default.
• W2149130129 creator A5065153513 @default.
• W2149130129 creator A5073298329 @default.
• W2149130129 date "2007-08-01" @default.
• W2149130129 modified "2023-10-16" @default.
• W2149130129 title "A Retrospective Evaluation of the Use of Gabapentin and Pregabalin in Patients with Postherpetic Neuralgia in Usual-Care Settings" @default.
• W2149130129 cites W1490401549 @default.
• W2149130129 cites W1613847106 @default.
• W2149130129 cites W183288359 @default.
• W2149130129 cites W1964575045 @default.
• W2149130129 cites W1964778524 @default.
• W2149130129 cites W1966324171 @default.
• W2149130129 cites W1971005199 @default.
• W2149130129 cites W1971020268 @default.
• W2149130129 cites W1975482756 @default.
• W2149130129 cites W1981435820 @default.
• W2149130129 cites W1984010212 @default.
• W2149130129 cites W1994111485 @default.
• W2149130129 cites W1997048153 @default.
• W2149130129 cites W2003520913 @default.
• W2149130129 cites W2006733509 @default.
• W2149130129 cites W2010942808 @default.
• W2149130129 cites W2011913908 @default.
• W2149130129 cites W2016027137 @default.
• W2149130129 cites W2019100545 @default.
• W2149130129 cites W2019364045 @default.
• W2149130129 cites W2020718971 @default.
• W2149130129 cites W2021113657 @default.
• W2149130129 cites W2021386245 @default.
• W2149130129 cites W2035274560 @default.
• W2149130129 cites W2039982019 @default.
• W2149130129 cites W2040032713 @default.
• W2149130129 cites W2047560765 @default.
• W2149130129 cites W2055967275 @default.
• W2149130129 cites W2057621238 @default.
• W2149130129 cites W2057983296 @default.
• W2149130129 cites W2060604906 @default.
• W2149130129 cites W2070246197 @default.
• W2149130129 cites W2071709883 @default.
• W2149130129 cites W2073543688 @default.
• W2149130129 cites W2077547311 @default.
• W2149130129 cites W2081154281 @default.
• W2149130129 cites W2081887464 @default.
• W2149130129 cites W2082940913 @default.
• W2149130129 cites W2084932194 @default.
• W2149130129 cites W2091943290 @default.
• W2149130129 cites W2097142258 @default.
• W2149130129 cites W2098577041 @default.
• W2149130129 cites W2101820523 @default.
• W2149130129 cites W2102023851 @default.
• W2149130129 cites W2103289578 @default.
• W2149130129 cites W2104333617 @default.
• W2149130129 cites W2104543475 @default.
• W2149130129 cites W2105305534 @default.
• W2149130129 cites W2119617723 @default.
• W2149130129 cites W2119931634 @default.
• W2149130129 cites W2121270079 @default.
• W2149130129 cites W2122540356 @default.
• W2149130129 cites W2129679700 @default.
• W2149130129 cites W2129860136 @default.
• W2149130129 cites W2133046934 @default.
• W2149130129 cites W2134255029 @default.
• W2149130129 cites W2136743000 @default.
• W2149130129 cites W2136779819 @default.
• W2149130129 cites W2138676765 @default.
• W2149130129 cites W2145888345 @default.
• W2149130129 cites W2149930373 @default.
• W2149130129 cites W2150775151 @default.
• W2149130129 cites W2158087005 @default.
• W2149130129 cites W2158523533 @default.
• W2149130129 cites W2159609548 @default.
• W2149130129 cites W2161563980 @default.
• W2149130129 cites W2168209429 @default.
• W2149130129 cites W2322450883 @default.
• W2149130129 cites W33374171 @default.
• W2149130129 cites W4233470361 @default.
• W2149130129 doi "https://doi.org/10.1016/j.clinthera.2007.08.019" @default.
• W2149130129 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17919547" @default.
• W2149130129 hasPublicationYear "2007" @default.
• W2149130129 type Work @default.
• W2149130129 sameAs 2149130129 @default.
• W2149130129 citedByCount "55" @default.
• W2149130129 countsByYear W21491301292012 @default.
• W2149130129 countsByYear W21491301292013 @default.
• W2149130129 countsByYear W21491301292014 @default.
• W2149130129 countsByYear W21491301292015 @default.
• W2149130129 countsByYear W21491301292016 @default.
• W2149130129 countsByYear W21491301292017 @default.
• W2149130129 countsByYear W21491301292018 @default.
• W2149130129 countsByYear W21491301292019 @default.
• W2149130129 countsByYear W21491301292021 @default.
• W2149130129 countsByYear W21491301292022 @default.
• W2149130129 crossrefType "journal-article" @default.
• W2149130129 hasAuthorship W2149130129A5030523303 @default.
• W2149130129 hasAuthorship W2149130129A5049491343 @default.

• next